Prior authorization bans for buprenorphine alone may not improve treatment retention

State laws that ban insurance prior authorization for buprenorphine—a leading medication for opioid use disorder—may not help more patients stay in treatment for the recommended minimum of 180 days, Weill Cornell Medicine researchers report….

Continue Reading

News Source: medicalxpress.com